6YY5 | pdb_00006yy5

Crystal structure of the ferric enterobactin receptor (PfeA) in complex with TCV_L5


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.72 Å
  • R-Value Free: 
    0.258 (Depositor), 0.239 (DCC) 
  • R-Value Work: 
    0.214 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 6YY5

Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history

Literature

Hijacking of the Enterobactin Pathway by a Synthetic Catechol Vector Designed for Oxazolidinone Antibiotic Delivery in Pseudomonas aeruginosa.

Moynie, L.Hoegy, F.Milenkovic, S.Munier, M.Paulen, A.Gasser, V.Faucon, A.L.Zill, N.Naismith, J.H.Ceccarelli, M.Schalk, I.J.Mislin, G.L.A.

(2022) ACS Infect Dis 

  • DOI: https://doi.org/10.1021/acsinfecdis.2c00202
  • Primary Citation Related Structures: 
    5NC3, 6Y47, 6YY5, 6Z2N, 6Z33, 7OBW

  • PubMed Abstract: 

    Enterobactin (ENT) is a tris-catechol siderophore used to acquire iron by multiple bacterial species. These ENT-dependent iron uptake systems have often been considered as potential gates in the bacterial envelope through which one can shuttle antibiotics (Trojan horse strategy). In practice, siderophore analogues containing catechol moieties have shown promise as vectors to which antibiotics may be attached. Bis- and tris-catechol vectors (BCVs and TCVs, respectively) were shown using structural biology and molecular modeling to mimic ENT binding to the outer membrane transporter PfeA in Pseudomonas aeruginosa . TCV but not BCV appears to cross the outer membrane via PfeA when linked to an antibiotic (linezolid). TCV is therefore a promising vector for Trojan horse strategies against P. aeruginosa , confirming the ENT-dependent iron uptake system as a gate to transport antibiotics into P. aeruginosa cells.


  • Organizational Affiliation
    • The Rosalind Franklin Institute, Harwell Campus, Oxfordshire OX11 0QS, U.K.

Macromolecule Content 

  • Total Structure Weight: 80 kDa 
  • Atom Count: 5,427 
  • Modeled Residue Count: 698 
  • Deposited Residue Count: 724 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Ferric enterobactin receptorA [auth AAA]724Pseudomonas aeruginosa PAO1Mutation(s): 0 
Gene Names: pfeAPA2688
Membrane Entity: Yes 
UniProt
Find proteins for Q05098 (Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1))
Explore Q05098 
Go to UniProtKB:  Q05098
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ05098
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 2 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
QDQ
(Subject of Investigation/LOI)

Query on QDQ



Download:Ideal Coordinates CCD File
C [auth AAA]~{N}-[2-[[(2~{S})-3-[[(2~{S})-3-[[1-[2-[2-[2-[4-[4-[5-(acetamidomethyl)-2-oxidanylidene-1,3-oxazolidin-3-yl]-2-fluoranyl-phenyl]piperazin-1-yl]-2-oxidanylidene-ethoxy]ethoxy]ethyl]-1,2,3-triazol-4-yl]methylamino]-2-[[2,3-bis(oxidanyl)phenyl]carbonylamino]-3-oxidanylidene-propyl]amino]-2-[[2,3-bis(oxidanyl)phenyl]carbonylamino]-3-oxidanylidene-propyl]amino]-2-oxidanylidene-ethyl]-2,3-bis(oxidanyl)benzamide
C54 H62 F N13 O18
OQJXSZUYGZCTKY-ACLHFTIQSA-N
FE

Query on FE



Download:Ideal Coordinates CCD File
B [auth AAA]FE (III) ION
Fe
VTLYFUHAOXGGBS-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.72 Å
  • R-Value Free:  0.258 (Depositor), 0.239 (DCC) 
  • R-Value Work:  0.214 (Depositor) 
Space Group: P 21 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 85.795α = 90
b = 157.049β = 90
c = 77.503γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
xia2data reduction
xia2data scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Innovative Medicines InitiativeUnited Kingdom--

Revision History  (Full details and data files)

  • Version 1.0: 2020-07-29
    Type: Initial release
  • Version 1.1: 2022-08-17
    Changes: Database references, Derived calculations
  • Version 1.2: 2024-01-24
    Changes: Data collection, Refinement description
  • Version 1.3: 2024-10-23
    Changes: Structure summary